AKYA — Akoya Biosciences Balance Sheet
0.000.00%
Last trade - 00:00
- $101.24m
- $116.49m
- $96.63m
- 34
- 35
- 36
- 27
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 21.7 | 17 | 113 | 81.2 | 83.1 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 13.2 | 6.47 | 9.44 | 9.73 | 17 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 40.9 | 28.7 | 141 | 112 | 122 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5.46 | 7.02 | 10 | 24.5 | 21.5 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 89.4 | 77.7 | 191 | 176 | 180 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 21.2 | 17.2 | 27.7 | 37.1 | 35.3 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 55.2 | 59.6 | 69.6 | 117 | 127 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 34.2 | 18.1 | 121 | 58.6 | 53.8 |
Total Liabilities & Shareholders' Equity | 89.4 | 77.7 | 191 | 176 | 180 |
Total Common Shares Outstanding |